DBV Technologies (NASDAQ:DBVT) Rating Reiterated by JMP Securities

JMP Securities reissued their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Tuesday, Benzinga reports. JMP Securities currently has a $5.00 price objective on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright reaffirmed a buy rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. StockNews.com began coverage on shares of DBV Technologies in a research report on Thursday, September 19th. They issued a hold rating on the stock.

DBV Technologies Price Performance

DBVT opened at $0.69 on Tuesday. The company’s 50 day moving average price is $0.87 and its two-hundred day moving average price is $1.08. The firm has a market capitalization of $66.10 million, a price-to-earnings ratio of -0.82 and a beta of 0.68. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.74.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the previous year, the company earned ($0.26) earnings per share. As a group, equities research analysts predict that DBV Technologies will post -1.43 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.